We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+20.6%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$63.1M
AUM Growth
-$19.4M
Cap. Flow
-$10.3M
Cap. Flow %
-16.33%
Top 10 Hldgs %
86.31%
Holding
30
New
4
Increased
1
Reduced
3
Closed
10

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$2.03M
2
AMRN
Amarin Corp
AMRN
+$1.26M

Top Sells

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$9.07M
2
AORT icon
Artivion
AORT
+$3.78M
3
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$749K

Sector Composition

Rank Sector Weight
1 Healthcare 84.51%
2 Miscellaneous 15.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANIP icon
1
ANI Pharmaceuticals
ANIP
$1.69B
$13.3M 21.02%
200,000
-145,000
-42% -$9.07M
ASRT
2
DELISTED
Assertio
ASRT
$8.74M 13.84%
5,833
– –
PFE icon
3
Pfizer
PFE
$160B
$5.93M 9.39%
184,450
– –
DGX icon
4
Quest Diagnostics
DGX
$27B
$5.6M 8.87%
66,208
– –
AMRI
5
DELISTED
Albany Molecular Research Inc
AMRI
$4.99M 7.91%
302,400
– –
QLTI
6
DELISTED
QLT Inc
QLTI
$4.44M 7.04%
2,157,200
– –
ANIP icon
7
PUT
ANI Pharmaceuticals
ANIP
$1.69B
$3.32M 5.26%
50,000
– –
ARLZ
8
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$2.79M 4.42%
575,000
– –
GILD icon
9
CALL
Gilead Sciences
GILD
$185B
$2.77M 4.39%
+35,000
New +$2.84M
AORT icon
10
Artivion
AORT
$1.3B
$2.64M 4.18%
150,000
-250,000
-63% -$3.78M
GILD icon
11
Gilead Sciences
GILD
$185B
$1.98M 3.13%
+25,000
New +$2.03M
AMAG
12
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$1.84M 2.91%
75,000
-30,000
-29% -$750K
AMRN
13
Amarin Corp
AMRN
$299M
$1.44M 2.27%
+22,500
New +$1.26M
CYTK icon
14
Cytokinetics
CYTK
$10.8B
$918K 1.45%
100,000
– –
TWM icon
15
ProShares UltraShort Russell2000
TWM
$44M
$721K 1.14%
1,250
– –
VIRX
16
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$656K 1.04%
4,286
+3,572
+500% +$504K
KITE
17
PUT
DELISTED
Kite Pharma, Inc.
KITE
$480K 0.76%
+8,600
New +$479K
ZGNX
18
DELISTED
Zogenix, Inc.
ZGNX
$364K 0.58%
31,850
– –
SEEL
19
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
FCSC
20
DELISTED
Fibrocell Science Inc.
FCSC
$106K 0.17%
9,851
– –
AORT icon
21
CALL
Artivion
AORT
$1.3B
– –
-50,000
Closed -$591K
ASRT
22
CALL
DELISTED
Assertio
ASRT
– –
-1,667
Closed -$1.96M
SPY icon
23
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$827B
– –
-75,000
Closed -$15.7M
TWM icon
24
CALL
ProShares UltraShort Russell2000
TWM
$44M
– –
-2,500
Closed -$1.74M
VIXY icon
25
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$212M
– –
-63
Closed -$916K
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Healthcare Value Capital held 30 positions worth $63.1M, down 23% from $82.5M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Healthcare Value Capital withdrew a net $10.3M in Q3 2016, closing 10 positions and reducing 3 holdings. Its most notable exit was SAGENT PHARMACEUTICALS INC COM STK (DE), an estimated $749K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 64% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital opened a new position in Gilead Sciences worth $1.98M.

  • Healthcare Value Capital's largest Q3 2016 buy was Gilead Sciences: 25,000 shares worth $1.98M.
  • Healthcare Value Capital's biggest Q3 2016 reduction was ANI Pharmaceuticals, cutting an estimated $9.07M.
  • Healthcare Value Capital fully exited SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2016, selling an estimated $749K.
  • Healthcare Value Capital's ten largest holdings make up 86% of its $63.1M portfolio in Q3 2016.
  • Healthcare Value Capital opened 4 new positions and closed 10 in Q3 2016.
  • Healthcare Value Capital's portfolio value fell 23% quarter-over-quarter to $63.1M.

Based on Healthcare Value Capital's 13F filing for Q3 2016, filed 10 Nov 2016.